| Anti‐monoclonal antibody treatment during pregnancy and lactation in women with multiple sclerosis or neuromyelitis optica spectrum disorder | | |
| Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021 | | 2022 |
| Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020 | | 2022 |
| Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different | | 2022 |
| Quality of life of children with mucopolysaccharidoses on the background of enzyme replacement therapy | | 2022 |
| Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study | Journal of Cancer Research and Clinical Oncology | |
| The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland | BioDrugs | 2022 |
| Seizure medication and planned pregnancy: balancing the risks and outcomes | Expert Review of Neurotherapeutics | |
| Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and health-related quality of life) | Bulletin Du Cancer | 2022 |
| Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience | BioDrugs | |
| Data-sharing and re-analysis for main studies assessed by the European Medicines Agency-a cross-sectional study on European Public Assessment Reports. | BMC Medicine | 2022 |
| Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. | JAMA Internal Medicine | 2022 |
| The characteristics of patents impacting availability of biosimilars. | Nature Biotechnology | 2022 |
| Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews. | Frontiers in Pharmacology | 2021 |
| Effectiveness of Vaccination against SARS-CoV-2 Infection in the Pre-Delta Era: A Systematic Review and Meta-Analysis. | Vaccines | 2022 |
| Hazardous drugs (NIOSH's list-group 1) in healthcare settings: Also a hazard for the environment? | Science of the Total Environment | 2022 |
| Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase the WHO Global Database of Individual Case Safety Reports | Cancers | 2021 |
| Cooperation in Pharmaceutical Development | Studies in Systems, Decision and Control | 2021 |
| Impact of non-formulary drugs on pharmacological prescription in hospitalised patients | European Journal of Hospital Pharmacy | 2021 |
| AIFA time-to-reimbursement: a comparison between the last two committees from 2015 to 2020 | Global & Regional Health Technology Assessment | 2020 |
| Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options | Dermatology and Therapy | 2021 |
| Monoclonal Antibodies for Protozoan Infections: A Future Reality or a Utopic Idea? | Frontiers in Medicine | 2021 |
| Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study | BioDrugs | 2021 |
| Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective | Drugs | 2021 |
| Checkpoint-Inhibition bei Tumorerkrankungen | Onkologe | 2021 |
| Free-of-charge medicine schemes in the NHS: A local and regional drug and therapeutic committee's experience | British Journal of Clinical Pharmacology | 2021 |
| Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe | JAMA Oncology | 2021 |
| A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab | Frontiers in Medicine | 2021 |
| Cost to Medicare of Delayed Adalimumab Biosimilar Availability | Clinical Pharmacology and Therapeutics | 2021 |
| Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis | Pharmacology Research and Perspectives | 2021 |
| Glutamate and depression: Reflecting a deepening knowledge of the gut and brain effects of a ubiquitous molecule | World Journal of Psychiatry | 2021 |
| Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis | Systematic Reviews | 2021 |
| Oncology Products in the European Union: An Analysis of Regulatory Approvals with a CHMP Oral Explanation | Therapeutic Innovation and Regulatory Science | 2021 |
| Recent developments of HDAC inhibitors: Emerging indications and novel molecules | British Journal of Clinical Pharmacology | 2021 |
| Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval | JAMA Internal Medicine | 2021 |
| Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products | Pharmaceutical Research | 2021 |
| Horizons in Veterinary Precision Oncology: Fundamentals of Cancer Genomics and Applications of Liquid Biopsy for the Detection, Characterization, and Management of Cancer in Dogs | Frontiers in Veterinary Science | 2021 |
| Dynamics of patents, orphan drug designation, licensing, and revenues from drugs for rare diseases: The market expansion of eculizumab | PLoS ONE | 2021 |
| The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization | Diagnostics | 2021 |
| A Systematic Review of the European Rapid Alert System for Food and Feed: Tendencies in Illegal Food Supplements for Weight Loss | Frontiers in Pharmacology | 2020 |
| Molecular engineering of antimicrobial peptides: microbial targets, peptide motifs and translation opportunities | Biophysical Reviews | 2021 |
| An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004-2018) | Perspectives in Clinical Research | 2021 |
| The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis | European Journal of Neurology | 2021 |
| Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis | Expert Review of Clinical Immunology | 2021 |
| Aggressiveness of end-of-life cancer care: what happens in clinical practice? | Supportive Care in Cancer | 2021 |
| Meta-analysis Comparing Fluorescence Imaging with Radioisotope and Blue Dye-Guided Sentinel Node Identification for Breast Cancer Surgery | Annals of Surgical Oncology | 2021 |
| Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects | Drugs and Aging | 2020 |
| Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review | Clinical Pharmacokinetics | 2020 |
| FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis | Cancers | 2020 |
| Clinical development success rates and social value of pediatric Phase 1 trials in oncology | PLoS ONE | 2020 |
